Abstract
Optimism about the possible clinical applications of monoclonal antibodies has fuelled this burgeoning part biomedical research for nearly a decade. The highest expectations centre on the use of radiolabelled monoclonal antibodies in the diagnosis and treatment of cancer. This paper attempts to evaluate the claims for the new technology. A review indicates that the technique is having a limited impact on the practical management of patients. It is suggested that these limitations are mainly because the expected speed of transfer of the technology from research laboratory to clinic may have been previously exaggerated. In the long term the evidence reviewed in this paper suggests that radiolabelled monoclonal anti-tumour antibodies offer the potential of making the next great step forward in the diagnosis and treatment of cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
